Precigen, Inc. Research and Development Expense of Revenue

Research and Development Expense of Revenue of PGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development Expense of Revenue for the quarter ending June 29, 2021 was 40.74% (a -5.08% decrease compared to previous quarter)
  • Year-over-year quarterly Research and Development Expense of Revenue decreased by -20.95%
  • Annual Research and Development Expense of Revenue for 2020 was 40.36% (a -45.07% decrease from previous year)
  • Annual Research and Development Expense of Revenue for 2019 was 73.48% (a -69.67% decrease from previous year)
  • Annual Research and Development Expense of Revenue for 2018 was 242.26% (a 290.74% increase from previous year)
  • Twelve month Research and Development Expense of Revenue ending June 29, 2021 was 32.42% (a -4.65% decrease compared to previous quarter)
  • Twelve month trailing Research and Development Expense of Revenue increased by 39.08% year-over-year
Trailing Research and Development Expense of Revenue for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
32.42% 34.0% 33.03% 23.31%
Visit stockrow.com/PGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development Expense of Revenue of Precigen, Inc.

Most recent Research and Development Expense of Revenueof PGEN including historical data for past 10 years.

Interactive Chart of Research and Development Expense of Revenue of Precigen, Inc.

Precigen, Inc. Research and Development Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 40.74% 42.92%
2020 -18.67% 51.54% 46.7% 37.96% 40.36%
2019 -83.39% 140.26% 86.0% 119.27% 73.48%
2018 617.97% 138.33% 92.87% 93.95% 242.26%
2017 6.91% 79.26% 62.48% 63.59% 62.0%
2016 62.76% 59.27% 54.05% 59.52% 58.73%
2015 63.13% 40.47% 45.4% 234.3% 84.95%
2014 56.73% 70.06% 122.46% 153.53% 82.0%
2013 175.7% 176.63% 201.94% 293.72% 202.62%
2012 491.08% 647.14% 464.89%
2011 876.43%

Business Profile of Precigen, Inc.

Sector: Healthcare
Industry: Biotechnology
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.